In humans, mutations in TPP1 and CTSD cause the CLN2 and CLN10 subtypes of NCL, respectively, and CTSB has been identified as a potential biomarker for CLN6 disease (Huber, 2021). Here, CLN6 is linked to neuronal ceroid lipofuscinosis.